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A B S T R A C T
Hallmarks of cancer cells include uncontrolled growth and rapid proliferation; thus, cyclin-dependent kinases
are a therapeutic target for cancer treatment. Treating non-small lung cancer cells with sublethal concentrations
of the CDK4/6 inhibitors, ribociclib (LEE011) and palbociclib (PD0332991), which are approved by the FDA for
anticancer therapies, caused cell cycle arrest in the G1 phase and suppression of poly(ADP-ribose) polymerase 1
(PARP1) transcription by inducing recruitment of the RB1-E2F1-HDAC1-EZH2 repressive complex to the PARP1
promoter. Downregulation of PARP1 made cancer cells vulnerable to death triggered by the anticancer drugs
(WP631 and etoposide) and H2O2. All agents brought about redox imbalance and DNA strand breaks. The lack of
PARP1 and poly(ADP-ribosyl)ation impaired the 8-oxoguanine glycosylase (OGG1)-dependent base excision
DNA repair pathway, which is critical for maintaining the viability of cells treated with CDK4/6 inhibitors
during oxidative stress. Upon G1 arrest of PARP1 overexpressing cells, OGG1 formed an immunoprecipitable
complex with PARP1. Similar to cells with downregulated PARP1 expression, inhibition of PARP1 or OGG1 in
PARP1 overexpressing cells resulted in DNA damage and decreased viability. Thus, PARP1 and OGG1 act in the
same regulatory pathway, and PARP1 activity is required for OGG1-mediated repair of oxidative DNA damage in
G1-arrested cells. In conclusion, the action of CDK4/6 inhibitors is not limited to the inhibition of cell growth.
CDK4/6 inhibitors also lead to accumulation of DNA damage by repressing PARP1 in oxidatively stressed cells.
Thus, CDK4/6 inhibitors sensitize G1-arrested cells to anticancer drugs, since these cells require PARP1-OGG1
functional interaction for cell survival.
1. Introduction
A growing number of people are diagnosed with cancer every year
prompting scientists to search for eﬃcient and selective tools for killing
transformed and fast proliferating cancer cells. Inhibition of cyclin
dependent kinases 4 and 6 (CDK4/6) is a plausible treatment option
which has been tested in several clinical trials. Two CDK4/6 inhibitors,
LEE011 (ribociclib, Kisqali) and PD0332991 (palbociclib, Imbrance),
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have recently been approved by the US Food and Drug Administration
for the treatment of advanced or metastatic breast cancer in combina-
tion with an aromatase inhibitor [1–3]. Following association with
corresponding cyclins, CDKs 4/6 become activated and phosphorylate
retinoblastoma protein (RB1), thereby preventing RB1 from binding to
and repressing E2F-dependent promoters. E2F-dependent promoters
control the transcription of genes encoding inter alia proteins capable of
promoting cell transition from G1 to S phase. Inhibition of CDK4/6
results in hypophosphorylation of RB1 and assembly of RB1-E2F-based
repressor complexes. These complexes consist of histone remodeling
enzymes, including histone deacetylases (HDACs), enhancer of zeste 2
polycomb repressive complex 2 subunit (EZH2), and SWI/SNF related,
matrix associated, actin dependent regulator of chromatin, subfamily a,
member 4 (SMARCA4), which erase transcription activating marks and
compact chromatin at gene regulatory elements to inhibit gene ex-
pression [4].
Retinoblastoma proteins are involved in the suppression of poly
(ADP-ribose) polymerase-1 (PARP1) in human monocytes and in
monocytic proliferating precursors upon growth arrest, as we have
shown previously [5]. In diﬀerentiated cells, the PARP1 promoter was
deacetylated by the RBL2-E2F4 dimer-associated HDAC1. On the other
hand, in G1-inhibited CD34+ hematopoietic stem cells, RB1-E2F1 re-
cruitment to the promoter was followed by histone deacetylation and
trimethylation of H3K27 carried out by HDAC1 (histone deacetylase 1)
and EZH2 (enhancer of zeste 2 polycomb repressive complex 2 sub-
unit), respectively. Therefore, hypophosphorylation of retinoblastoma
family members by the application of CDK4/6 inhibitors may suppress
PARP1 transcription in fast growing cancer cells. PARP1 protein and
protein poly(ADP-ribosyl)ation (PARylation) by PARP1 are involved in
the regulation of many intracellular processes, such as signaling, me-
tabolism, gene expression, and DNA repair. Therefore, there is growing
interest in the application of PARP1 inhibitors in cancer treatment.
PARP1 activation, in response to DNA breaks, leads to mostly auto-
PARylation, which acts as a landing platform for the recruitment of
DNA repair complexes [6]. These repair pathways include single strand
break repair and base excision repair (SSBR and BER: XRCC1, OGG1,
DNAP β, DNA ligase III, PCNA, aprataxin, and condensin I), as well as
double strand break repair via homologous recombination (HR) (active
mostly in S and G2 phases) and non-homologous end joining (NHEJ,
active in all cell cycle phases) by interacting with MRE11, RAD51,
DNA-PKcs/Ku, and DNA ligase IV. PARP1 inhibitors are used in cancer
therapies in the setting of BRCA1 (breast cancer type 1 susceptibility
protein) or BRCA2 (breast cancer type 2 susceptibility protein) loss
(olaparib and rucaparib approved by FDA in patients with HR dys-
function). Clinical trials using PARP1 inhibitors in combination therapy
with DNA damaging agents have been conducted recently in HR-deﬁ-
cient and HR-competent tumors [7].
In G1 arrest, repair of double strand breaks shifts from error-free HR
to error-prone NHEJ, in which PARP1 plays a suppressive role [8].
PARP1 deﬁciency releases DNA-PKcs activity, leading to accumulation
of DNA errors, and eventually to cell death [9]. Furthermore, by default
single strand damages are repaired by BER and SSBR in cells deprived
of HR. Quite recently, Noren Hooten described the physical and func-
tional interaction between PARP1 and OGG1 in BER in response to
oxidative stress [10]. Oxidative stress, induced by administration of
chemical agents, which impair redox homeostasis or by direct cell/
tissue irradiation, is often applied as a cancer treatment strategy. OGG1
removes the highly mutagenic 7,8-dihydro-8-oxoguanine (8-oxo-Gua)
and 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyGua) lesions
from DNA, while the loss of OGG1 activity increases the cytotoxicity of
multiple therapeutic drugs and IR [11].
Our study indicates that PARP1 is indispensable for OGG1-depen-
dent BER in G1-arrested cells challenged with anticancer drugs, which
cause oxidant stress. These drugs, WP631 and etoposide, or the direct
oxidant, hydrogen peroxide, caused single (but not double) strand
breaks and accumulation of 8-oxo-Gua. PARP1 deﬁciency, resulting
from administration of CDK4/6 inhibitors, impairs OGG1-dependent
BER and sensitizes cancer cells to oxidative imbalance-induced death.
2. Materials and methods
2.1. Materials
The A549 cell line was from ATCC (USA). Cell culture media were
purchased from Biowest (CytoGen, Zgierz, Poland). The following an-
tibodies for western blotting were from Santa Cruz Biotechnology
(AMX, Łódź, Poland): anti-PARP1 (sc-8007), anti-α-tubulin (sc-5546),
anti-pADPribose (10 H, sc- 56198), and gallotannin. TRI Reagent, so-
dium butyrate (iHDAC), anti-rabbit IgG (A0545) and goat anti-mouse
IgG (A4416) (whole molecule)–peroxidase conjugate, hygromycin B,
the OGG1 inhibitor O8 were from Sigma Aldrich (Poznan, Poland). The
following ChIP grade antibodies were purchased from Cell Signaling
Technology (LabJOT, Warsaw, Poland): anti-histone H3 (#4620), anti-
H3K27me3 (#9733), anti-RB1 (#9313), anti-E2F1 (#3742), normal
rabbit IgG (#2729). Anti-acetyl-histone H3 (Lys9 + Lys14) (PA5-
16194), anti-HDAC1 (PA1-860), Texas Red™-X Phalloidin (T7471),
Dynabeads™ Protein G, High-Capacity cDNA Reverse Transcription Kit,
SuperSignal™ West Pico Chemiluminescent Substrate, MitoTracker™
Red CMXRos and DAPI were from Thermoﬁsher Scientiﬁc (Warsaw,
Poland). LEE011 (Ribociclib), PD0332991 (Palbociclib), and NU 6140
were purchased from Cayman Europe (Biokom, Janki/Warsaw,
Poland). Kapa Sybr Fast qPCR Master Mix and KAPA HiFi™ HotStart
ReadyMix (2×) were purchased from Kapa Biosystems (Polgen, Łódź,
Poland). ViaFect™ Transfection Reagent was purchased from Promega
(Warsaw, Poland). The human PARP1 Gene cDNA Clone (full-length
ORF Clone), expression ready, untagged (HG11040-UT; pCMV3-
PARP1) and pCMV3-untagged Negative Control Vector (CV011;
pCMV3-EMPTY) were purchased from Hölzel Diagnostika Handels
GmbH (Köln, Germany). EvaGreen® Dye, 20× in water was purchased
from Biotium (Corporate Place Hayward, USA). Annexin V-FITC
Apoptosis Detection Kit I was purchased from Becton Dickinson (Diag-
med, Warsaw, Poland). Anti-DNA/RNA Damage antibody [15A3]
(FITC) (ab183393) was from Abcam (Bio-Kasztel, Hungary). Human 8-
oxoGuanine DNA Glycosylase and 10× REC™ Buﬀer 6 was from
Trevigen (Nordic BioSite OY, Helsinki, Finland).
2.2. Cell culture and treatment
A549 cells (non-small lung carcinoma cells derived from primary
tumor, passage 10–25) were cultured in DMEM supplemented with 10%
FBS and penicillin/streptomycin solution (50 U/ml and 50 µg/ml, re-
spectively). For cell arrest in G1 phase, cells were treated with 2 µM of
LEE011 and 1 µM PD0332991 for 48 h. For cell cycle arrest in G2, cells
were treated with 10 µM NU6140 for 48 h. To induce redox stress, cells
were treated with hydrogen peroxide [H2O2], WP631, or etoposide. Cell
cycle was arrested by treating cells with CDK4/6 inhibitors for 48 h
prior to challenging them with oxidative stimuli.
To study the contribution of HDAC(s) and PRC2 to suppression of
PARP1 during growth inhibition, cells cultured in the presence of
iCDK4/6 for 24 h were then treated with iHDAC (pan-HDAC inhibitor;
0.5 mM) and iPRC2 (EZH2 inhibitor; 0.125 nM) for an additional 24 h.
2.3. Cell viability
Cell viability was determined with MTT assay as previously de-
scribed [12]. Determination of the mode of cell death was carried out
by AnnexinV/propidium iodide staining. Fluorescence was measured
by BD LSR II Flow Cytometer according to the protocol described in
Robaszkiewicz A et al. [13].
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2.4. Analysis of the cell cycle
For cell cycle analysis, DNA was stained with propidium iodide
followed by ﬂow cytometry measurement of the DNA content as de-
scribed previously [12].
2.5. Evaluation of oxidative stress
Alteration of redox homeostasis was monitored with 2′,7′-di-
chlorodihydroﬂuorescein diacetate (H2DCF-DA) ﬂuorescent staining as
described by Tokarz et al. [14]. Although redox chemistry of hydro-
lyzed DCFH is complex and includes, among others, oxidation by cy-
tochrome c or redox active metals in the presence of superoxide or O2, it
mostly indicates oxidant stress [15]. The ﬂuorescence corresponding to
probe oxidation was normalized to DNA content, as estimated with
propidium iodide. Total thiol content was determined with mono-
bromobiname and normalized to total DNA content as described pre-
viously [12].
2.6. Generation of PARP1 overexpressing cell lines
A549 cells (passage 4) were transfected with pCMV3-EMPTY or
pCMV3-PARP1 expression vector using ViaFect™ Transfection Reagent.
In brief, 24 h after plating (approximately 100 000), cells were trans-
fected with the following mixture: 0.1 µg DNA and 0.8 µl ViaFect™
Transfection Reagent in OptiMem, and incubated for 15 min at room
temperature prior to cell treatment. Forty-eight hours after transfection,
cells were selected with hygromycin B for a month. RNA was extracted
with TRI Reagent and additionally treated with DNA-free™ DNA
Removal Kit before reverse transcription.
2.7. Western blot
Cells were lysed in RIPA buﬀer (10 mM Tris-HCl pH = 8.0, 140 mM
NaCl, 0.5% SDS) supplemented with a proteinase inhibitor cocktail and
1 mM PMSF. For poly-ADP-ribose detection, lysis buﬀer was also sup-
plemented with PARG inhibitor (1 mM gallotannin). For protein de-
tection, membranes were blocked with 1% BSA in PRB-Tween 20
(0.1%). For poly-ADP-ribose, membranes were blocked with 0.5% ge-
latin in PRB-Tween 20 (0.1%). Nitrocellulose membranes were stained
with primary antibody at 4 °C overnight, then incubated with perox-
idase-conjugated anti-rabbit or anti-mouse secondary antibodies (Sigma
Aldrich) for at least 2 h at room temperature. Signal was developed
using SuperSignal™ West Pico Chemiluminescent Substrate and ac-
quired with ChemiDoc-IT2 (UVP, Meranco, Poznan, Poland).
2.8. Gene expression
RNA was extracted with TRI Reagent, reversed transcribed (High
Capacity cDNA Reverse Transcription Kit, Thermoﬁsher Scientiﬁc), and
cDNA was quantiﬁed by real-time PCR using Kapa Sybr Fast qPCR
Master Mix and CFX96 C1000 Touch real time qPCR detection system
(Bio-Rad, Warsaw, Poland). The following primers were used for
PARP1: Fwd 5′-AAGCCCTAAAGGCTCAGAACG-3′ and Rev 5′-ACCATG
CCATCAGCTACTCGGT-3′. PARP1 expression was normalized to ACTB
(Fwd: 5′-TGGCACCCAGCACAATGAA-3′ and Rev 5′-CTAAGTCATAGTC
CGCCTAGAAGCA-3′).
2.9. Chromatin immunoprecipitation
Chromatin immunoprecipitation of E2F1, RB1, HDAC1, EZH2, H3,
acH3K9/14, and H3K27me3 was carried out according to Wiśnik et al.
[5]. The immunoprecipitated DNA (PARP1 promoter) was quantiﬁed
with real-time PCR using KAPA HiFi™ HotStart ReadyMix supple-
mented with EvaGreen® Dye and 7% DMSO. The following primers
were used: Fwd 5′-AACGCCCACGGAACCC-3′ and Rev 5′-CTACTAGCT
CAGCCCAAGCC-3′.
2.10. Protein co-immunoprecipitation
Cells were lysed in IP buﬀer (50 mM Tris-HCl pH = 7.5, 125 mM
KCl, 2.5 mM MgCl2, 0.1 mM CaCl2, 10% glycerol, 0.1% NP-40).
Subsequently, 5 µg rabbit anti-PARP1 antibody was added to 1 mg of
nuclear extracts for 3 h (4 °C). 1 h prior to the end of im-
munoprecipitation, 10 µl of Dynabeads™ Protein G was added to cell
lysates. Beads were washed ﬁve times with IP buﬀer, suspended in 50 µl
of RIPA buﬀer, and mixed with 6× SDS loading buﬀer. After heating at
75 °C for 10 min, beads were removed on magnetic stand and im-
munoprecipitated proteins were separated on 10% SDS-gel. Total cell
lysate (10%) was loaded on a gel as an input.
2.11. Comet assay
Alkaline and neutral version of the comet assay was performed as
described by Tokarz et al. [14]. For quantiﬁcation of 8-oxoguanosine in
genomic DNA, agarose-embedded and lysed cells were incubated with
human OGG1 in digestion buﬀer (1 U, 37 °C, 30 min), and then the
DNA was subjected to alkaline electrophoresis. The diﬀerence in the tail
DNA between OGG1 and buﬀer-treated samples corresponded to the
number of OGG1-sensitive sites [16].
2.12. Confocal microscopy
After ﬁxation with ice cold methanol for 5 min, cells were per-
meabilized with 0.1% Triton X100 for 30 min, blocked with 1% BSA/
0.1% Triton X100 for 1 h, and stained with a mixture of Texas Red™-X
Phalloidin (1:200) and anti-DNA/RNA Damage antibody (1:200) in the
blocking solution for 2 h. Nuclei were stained with 2 μg/ml DAPI in
PBS. Coverslips were mounted in Mowiol and then viewed with a Leica
TCS SP8 confocal microscope. Images were processed with a LAS AF
v3.1.3 software.
2.13. Statistical analysis
Data is presented as means± standard errors of the mean (SEM).
Student t-test was used to compare diﬀerences between two means. All
bars represent data from at least three independent biological replicates
(carried out on diﬀerent days and with cells of diﬀerent passage num-
bers) with two technical replicates each.
3. Results
To check the direct cytotoxicity of CDK4/6 (LEE011 and
PD0332991) and CDK2 (NU6140) inhibitors, we ﬁrst determined the
relative number of living cells after a 48 h treatment with diﬀerent
concentrations (0–50 µM) of the inhibitors. All compounds caused a
concentration-dependent inhibition of cell growth with IC70 values of
~ 2 µM, 1 µM, and 10 µM for LEE011, PD0332991, and NU1640, re-
spectively (Fig. 1A). At concentrations corresponding to their IC70
value, CDK inhibitors did not induce cell death (Fig. 1B), but eﬃciently
inhibited cell cycle progression by arresting cells in G1 (LEE011,
PD0332991) or in G2 (NU6140) (Fig. 1C). G1, but not G2, arrest sub-
stantially downregulated PARP1 expression, both at the protein and at
the mRNA level (Fig. 1D). Importantly, of the two CDK4/6 inhibitors,
PD0332991 had a stronger suppressive eﬀect on PARP1 expression. An
analysis of the PARP1 promoter revealed that CDK4/6 inhibitors trig-
gered the recruitment of the E2F1-RB1 repressive dimer to the PARP1
promoter (Fig. 1E). Furthermore, E2F1-RB1 binding was followed by
loss of the transcription promoting histone mark (acetylation of lysine 9
and 14 at histone 3) and by accumulation of the transcription silencing
mark (trimethylation of lysine 27 at histone 3). As expected from the
proﬁle of histone marks, PARP1 promoter was occupied by histone
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deacetylase 1 (HDAC1, Fig. 1E) and the histone methyltransferase,
EZH2, which is a functional enzymatic component of the Polycomb
Repressive Complex 2 (PRC2). Notably, PARP1 expression positively
correlated with the ac-H3K9/K14 mark and negatively correlated with
H3K27me3, HDAC1, and EZH2 recruitment to the PARP1 promoter. To
conﬁrm the functional role of HDAC1 and PRC2 in the regulation of
PARP1 expression, we tested the eﬀects of inhibitors of these enzymes
(iHDAC1, 0.5 mM; iPRC2, 0.125 nM). Although the PARP1 promoter
was enriched in EZH2 upon LEE011 administration, inhibition of
HDAC1 activity maintained PARP1 transcription. A further increase in
mRNA and protein levels of PARP1 was not observed if PRC2 was also
inhibited (Fig. 1F). However, in cells arrested with PD033291, si-
multaneous inhibition of HDAC1 and PRC2 was required to rescue
PARP1 level. Of note, PD0332991 treated cells were characterized by
more intense H3K27 trimethylation and higher HDAC1 and EZH2 oc-
currence when compared to cells treated with LEE011.
3.1. Oxidant stress caused by H2O2, WP631, and etoposide leads to damage
of nucleic acids and cell death
To evaluate the potential of WP631 and etoposide to trigger redox
imbalance, we ﬁrst measured the production of oxidants and the con-
tent of low molecular weight thiols inside cells. We used H2O2, as a
positive control. As shown in Fig. 2A, all of these agents led to oxidation
of the ﬂuorescent probe with the following eﬃcacy:
H2O2>WP631> etoposide. The thiol content negatively correlated
with H2DCF-DA ﬂuorescence. A similar proﬁle was observed for PARP1
activation and its auto-PARylation, where H2O2 stimulated the stron-
gest protein PARylation (Fig. 2B). The PARylation of PARP1 was pre-
vented when cells were pretreated with N-acetyl-cysteine (NAC, Sup-
plement Fig. 1A-C), indicating that oxidative is a bona ﬁde activator of
PARylation. A close correlation was also observed between DNA da-
mage and the oxidative stimulus. As for PARylation, all three agents
caused DNA damage (accumulation of 8-oxo-Gua and DNA breaks),
which was rescued by NAC (Fig. 2C). RNA oxidation was evidenced by
detection of Oxo-8-G (8-oxo-7,8-dihydroguanosine) in cytoplasmic RNA
(Fig. 2D, extended version in Supplement Fig. 2). Notably, despite the
observed impair in redox homeostasis, DNA double-strand breaks re-
mained at very low levels (around 1%) in all samples (Supplement
Fig. 1D; a neutral version of the comet assay). Furthermore, cell death
induced by all compounds (Fig. 2E-F) was mediated by oxidative sig-
naling, as indicated by the cytoprotective eﬀect of NAC. The treatment
of proliferating cells with H2O2, WP631, and etoposide triggered mostly
apoptosis, as indicated by annexin V positivity (Fig. 2F).
3.2. PARP1 repression by CDK4/6 inhibitors sensitizes G1-arrested cells to
redox imbalance-induced death
As shown in Fig. 3A, arresting cells in the G1 phase with LEE011
and PD0332991 considerably reduced the number of viable cells after
treatment with H2O2 and anticancer drugs compared to proliferating
cells. To check if the observed increase in toxicity of oxidative stimuli
was caused by PARP1 downregulation, we generated a cell line
(pCMV3-PARP1) to keep PARP1 protein and mRNA levels stable upon
G1 arrest. The control cell line (pCMV3-EMPTY) displayed PARP1
downregulation after growth inhibition with LEE011 and PD0332991
(Supplement Fig. 3A-B). In contrast to pCMV3-EMPTY, G1-arrested
cells overexpressing PARP1 retained PARylation capacity following
oxidative stress (Supplement Fig. 3C). Proliferating pCMV3-PARP1 and
pCMV3-EMPTY cells showed similar PARP1 levels and sensitivity to the
three agents (Suppl. Fig. 3A-B and B). However, upon G1 arrest induced
by both LEE011 and PD0332991, pCMV3-PARP1 cells showed sig-
niﬁcant resistance to the toxic eﬀects of H2O2 and anticancer drugs
(Fig. 3B). Data from MTT tests were conﬁrmed by annexin V/PI staining
of cells (Fig. 3C). Notably, in contrast to proliferating cells, pCMV3-
EMPTY cells treated with PD0332991 and DNA damaging agents
showed a substantial increase in single PI-positive cells (Fig. 2F, 3C).
These data suggest that cell growth inhibition followed by PARP1 re-
pression made cells vulnerable to necrosis, while sustained PARP1 ex-
pression protected cells in G1-arrest from DNA damage-induced cell
death.
To verify the contribution of PARylation to the protection of
growth-inhibited cells from DNA damage-induced cytotoxicity, we
tested the eﬀect of the PARylation inhibitor, olaparib (iPARP1) in
pCMV3-PARP1 cells. Olaparib alone or in combination with CDK4/6
inhibitors did not aﬀect cell viability (Supplement Fig. 3D). However,
inhibition of PARP1 activity completely abolished the protective eﬀect
of PARP1 overexpression on cell survival in LEE011/PD0332991 and
cytotoxin-treated cells (Fig. 3D).
3.3. PARP1 is required for OGG1-dependent BER in G1-arrested cells and
protects cells from toxicity caused by anticancer drugs
Since H2O2, WP631, and etoposide caused DNA damage, and PARP1
was reported to protect the genome, we set out to determine the eﬀects
of PARP1 repression on DNA damage repair mechanisms in growth-
arrested cells. As shown in Fig. 4A, even a short incubation with H2O2
led to statistically signiﬁcant diﬀerences in DNA strand break levels
between pCMV3-EMPTY and pCMV3-PARP1 cells. The discrepancy
became even more distinct after an additional 2 h incubation in the
absence of H2O2. PARP1 overexpressing cells challenged with H2O2
completely repaired DNA strand breaks regardless of G1 inhibition. On
the contrary, pCMV3-EMPTY cells were defective in DNA repair and the
accumulation of DNA damage correlated with the repression of PARP1
in response to LEE011 and PD0332991. A similar proﬁle of inter-
dependence between PARP1 level and the extent of DNA strand breaks
was observed in cells treated with WP631 and etoposide even before
the withdrawal of the toxic agent (Fig. 4A, left panels). Although some
decrease in DNA damage was found after WP631 removal, the pCMV3-
EMPTY cells treated with LEE011 and PD0332991 displayed a high
number of genomic lesions. Etoposide removal did not aﬀect the level
of DNA breaks in these cells (Fig. 4A, right panels). Neither WP631 nor
etoposide brought about accumulation of DNA lesions in pCMV3-
PARP1 cells.
Since these genotoxic agents cause oxidation of guanine, we
checked if OGG1 contributed to DNA break repair and if PARP1 is re-
quired for OGG1 activity. For this purpose, we pretreated G1-arrested
(PD0332991) pCMV3-PARP1 cells with PARP1 (iPARP1 - olaparib) and
OGG1 (iOGG1 – O8) inhibitors (separately and in combination). None
of these compounds caused DNA lesions in cells (Suppl. Fig. 3E).
However, inhibition of either one or both enzymes led to a substantial
and comparable accumulation of DNA strand breaks triggered by the
three genotoxic agents (Fig. 4B, upper panels). Similar to pCMV3-
EMPTY cells arrested with LEE011 and PD0332991, inhibition of
Fig. 1. Inhibition of CDK4/6 suppresses PARP1 expression by inducing formation of E2F1-RB1-HDAC1-PRC2/EZH2 repressive complex. The quantiﬁcation of living cells by MTT after
treatment with CDK4/6 inhibitors LEE011 and PD0332991, as well as with iCDK2 (NU6140) for 48 h is shown (A). The direct toxicity of LEE011 (2 µM), PD0332991 (1 µM), and NU6140
(10 µM) was analyzed by ﬂow cytometry 48 h after incubation with iCDKs (B). Q1 represents necrotic cells, Q2 – late apoptotic, Q3 – early apoptotic, and Q4 – living cells. Cell cycle
distribution of cells was determined by ﬂow cytometry after DNA staining with propidium iodide (C). The level of PARP1 protein and mRNA was assessed by western blot and real-time
PCR (D), respectively. The composition of repressive complex and histone modiﬁcations at the PARP1 promoter were determined by ChIP-qPCR (E). The contribution of HDAC1 and EZH2
to PARP1 repression was conﬁrmed by treating cells with iHDAC (sodium butyrate− 0.5 mM) and iEZH2 (UNC1999, 125 nM) in addition to LEE011 and PD0332991 (F). PARP1 protein
and mRNA recovery was monitored by western blot and real-time PCR, respectively. Bars in the ﬁgures represent mean± SEM, N = 3 (with three technical replicates per experiment for
panel A and two technical replicates for other panels), where * indicates p<0.05. Panels D and F show representative pictures.
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PARP1 or OGG1 maintained DNA lesions in pCMV3-PARP1 cells after
withdrawal of the toxic substances (Fig. 4B, lower panels). These data
indicate that PARylation is indispensable for the OGG1-dependent re-
pair of these DNA lesions in G1-arrested cells. The lack of synergism
between iPARP and iOGG1 suggests that both enzymes act in the same
regulatory pathway. The immunoprecipitation of PARP1 in growth in-
hibited (PD0332991) pCMV3-PARP1 cells revealed a functional inter-
action between these two enzymes (Fig. 4C). To verify the possible role
of OGG1 in cell survival in the presence of PARP1 and their mutual
cross-talk, we compared the viability of G1-arrested pCMV3-EMPTY
and pCMV3-PARP1 cells incubated with iOGG1 and iOGG1/iPARP1
prior to cell exposure to anticancer drugs and H2O2 (Fig. 4D). Similar to
PARP1 inhibition, OGG1 inhibition sensitized PARP1 overexpressing
cells and reduced the number of living cells to the level observed in the
corresponding pCMV3-EMPTY cells. Simultaneous inhibition of both
enzymes did not lead to further increase in cell death. Of note, neither
iPARP1 nor iOGG1 aﬀected the survival of pCMV3-EMPTY cells upon
alteration of redox homeostasis. Altogether these data indicate that
PARP1 repression in response to growth inhibition impairs OGG1–de-
pendent BER, thereby leading to increased sensitivity to the cytotoxic
eﬀects of anticancer drugs and H2O2.
4. Discussion
The discovery of the role of CDK 4/6 in cell cycle progression and
development of inhibitors allowed scientists to investigate the eﬀects of
CDK4/6 inhibitors in fast-proliferating cancer cells. Our study shows
that CDK4/6 inhibitors, even at sublethal concentrations, cause a con-
siderable decrease in PARP1 transcription, in addition to suppressing
lung cancer cell growth. Although both inhibitors arrested the cell cycle
in G1 phase, PD0332991 suppressed PARP1 expression more than
LEE011 (Fig. 1D). The G2 phase blocker NU1640 also stopped the cell
cycle, but did not aﬀect PARP1 expression. This ﬁnding indicates that
PARP1 downregulation is a speciﬁc event of the G1 phase. These
ﬁndings are in line with our previous observations made in THP-1 cells;
cells arrested in G1 (with mimosine), but not in G2 (with nocodazole),
lost their ability to maintain high PARP1 levels.
A diﬀerent composition of repressive complexes at the PARP1 pro-
moter may explain the diﬀerences in PARP1 suppression after treatment
with these CDK4/6 inhibitors. Both inhibitors induced the assembly of
the same repressive complex (E2F1-RB1-HDAC1-EZH2). However, en-
richment of these factors (except RB1) was higher in cells arrested with
PD0332991. Since histone acetylation was similar, EZH2 and
H2K27me3 are likely the key repressors of PARP1 expression. This was
conﬁrmed with iHDAC and iEZH2, because only PD0332991 treated
cells required both inhibitors for PARP1 derepression. Interestingly, the
level of E2F1 at the PARP1 promoter correlated with both HDAC1 and
EZH2. E2F1 has also been documented to repress genes independent of
RB1, and E2F1 activity is likely to be controlled by multiple factors.
Previously, E2F1 was shown to directly repress the gene of the anti-
apoptotic protein Mcl-1. The Rb1-independent interaction of E2F1 with
the class III histone deacetylase, SirT1 and HDAC1, through KAP1 has
also been demonstrated [17,18]. Furthermore, the binding of TopBP1 to
E2F1 was found to recruit SMARCA4 and SMARCA2 (the components of
the SWI/SNF chromatin-remodeling complex) and repress some of the
E2F1-dependent genes [19,20]. Thus, overrepresentation of E2F1 at the
PARP1 promoter in PD0332991-treated cells may be responsible for the
increased occurrence of HDAC1 and EZH2. However, the mechanisms
responsible for the strong accumulation of E2F1 on the PARP1 promoter
remain unknown and may display promoter and signal speciﬁcity.
Since CDK4/6 inhibitors eﬃciently repress PARP1 expression, their
therapeutic application should be reevaluated and extended from
simple growth inhibition to combination therapies involving DNA da-
maging agents. In this novel scenario, iCDK4/6-induced PARP1 deple-
tion could sensitize growth arrested cancer cells to cytotoxic agents.
The hitherto clinical application of PARP inhibitors is based on the
PARP-BRCA synthetic lethality paradigm, exploiting homologous re-
combination repair deﬁciency of tumors (e.g. due to germline BRCA1/2
mutation or a functional BRCA-ness phenotype) [21]. The latest ap-
proaches in synthetic lethality aim to use various PARP1 inhibitors
(talazoparib, veliparib, rucaparib, niraparib) for the treatment of can-
cers with defects other than BRCA1 deﬁciencies, including defects in
PALB2, FANCD2, RAD51, ATM, MRE11, p53, XRCC1 and LSD1 [22].
The knowledge on how to suppress PARP1 transcription extends the list
of potential partners to be targeted in order to develop synthetic leth-
ality. One must be cautious, however, not to equate PARP1 repression
with PARP1 inhibition. When PARP1 is inhibited the enzyme gets
trapped at DNA breaks and this feature is considered important to the
clinical activity of PARP inhibitors. Nonetheless, it may be worthwhile
to test the eﬃcacy of combination therapies with iCDK4/6 and DNA
damaging chemotherapeutics or irradiation.
Although CDK4/6 inhibitors sensitized A549 lung cancer cells to
death induced by the anticancer drugs, WP631 and etoposide, in vitro,
the idea of combining PARP1 repression should be considered on a case
by case basis and particular attention should be paid to the type of
cancer and death-inducing agents. One should always bear in mind that
PARP1 and PARylation regulate many intracellular processes. For ex-
ample, intense PARP1 activation (e.g. in response to severe DNA da-
mage) impairs cellular metabolism by NAD+ consumption. Therefore,
PARP1 deﬁciency or inhibition have been documented to prevent en-
ergetic failure (NAD+ and ATP depletion) [23,24]. Over-activation of
PARP1 may also function as a necrotic cell suicide mechanism in cells
exposed to intense oxidant stress. However, stimuli applied in our
current study caused less severe, repairable DNA damage [25,26]. At
the genomic level, PARP1 was documented to regulate transcription of
both tumor suppressors and oncogenes and eﬀectors of metastatic
processes (E-cadherin, ﬁbronectin). PARP1 was also shown to co-op-
erate with nuclear receptors (estrogen, progesterone and androgen re-
ceptors) in cancer cells [27]. Therefore, genomic and transcriptome
proﬁles should be checked before the administration of PARP1 sup-
pressive agents such as CDK4/6 inhibitors.
Another limitation in using the combinatory treatment (CDK4/6
inhibitors and DNA damaging agents) is the deﬁciency of RB1 in some
primary cancer cells, which has been linked to poor prognosis and al-
tered response to anticancer treatment [28–30]. The relatively fast
proliferating cancer cell line (A549) used in this study is positive for
both PARP1 and RB1 (as conﬁrmed by western blots – PARP1 and
chromatin immunoprecipitation in G1 arrested cells – RB1). Thus, it
allowed us to create a functional link between RB1, PARP1 and OGG1.
The lack of any of these three proteins or likely mediators between RB1
and PARP1 or PARP1 and OGG1 precludes the practical application of
the approach presented in this study. Previous studies have documented
that RB1 is mutated in most retinoblastomas, osteosarcomas, and small-
cell lung cancers, but also in other cancer types at lower frequencies
Fig. 4. PARP1 repression impairs OGG1-mediated repair of DNA lesions. Alkaline comet assay was used to quantify the level of DNA strand breaks in proliferating and G1 arrested cells
treated with the cytotoxic agents (H2O2− 50 μM; WP631 – 100 nM; and etoposide− 75 μM) (A). In the left panels, cells were treated with H2O2 for 15 min and with WP631 or etoposide
for 2 h. Afterwards, toxic agents were removed from the culture by washing with growth medium and cells were incubated at 37 °C for another 2 h (repair; right panels). To test the
contribution of PARP1 and OGG1 activity to the repair of oxidative DNA damage in G1-arrested pCMV3-PARP1 expressing cells (B, upper panels), cells were preincubated with iPARP1
(olaparib, 1 µM) or iOGG1 (O8, 10 µM) for 1 h. Afterwards, cells were treated and analyzed as described in A. In growth-arrested pCMV3-PARP1 cells treated with the toxic agents,
PARP1-OGG1 physical interaction was detected by co-immunoprecipitation (C). The eﬀect of PARP1 and OGG1 inhibition on the viability of G1-arrested cells was determined with MTT
testing (D). iPARP1 and iOGG1 were added to cells 1 h prior to addition of H2O2, WP631, and etoposide. Bars in the ﬁgures represent mean± SEM, N = 3 (with two technical replicates
per experiment), where * indicates p< 0.05;. Panel C shows representative images.
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[31]. RB1 deﬁciency makes cancer cells resistant to CDK4/6 inhibitors,
but may also prevent eﬃcient PARP1 gene targeting.
An interesting ﬁnding in our current work shed light on the re-
lationship of PARP1 and OGG1. Our ﬁndings suggest that PARP1 is
required for proper functioning of OGG1 in G1-arrested cells. However,
Noren Hooten et al. reported a bidirectional interplay between these
two proteins, identifying a direct, hydrogen peroxide-enhanced binding
of the proteins. Hooten found that OGG1 stimulated PARP1, while
PARP1 activity inhibited OGG1 function [10]. That observation was
made in proliferating HeLa cells, suggesting that PARP1-OGG1 cross-
talk is cell type or cell cycle progression dependent, rather than oxidant
dependent, since the interactions occurred in H2O2 treated cells.
PARP1 downregulation in G1-arrested cells or inhibition of PARP
activity in PARP1 overexpressing cells phenocopied the eﬀect of OGG1
inhibition on both DNA damage repair and cell viability. Thus, poly
(ADP-ribosyl)ation was indispensable for the maintenance of genome
integrity and cell survival. In human lens epithelial cells (HLE-B3)
challenged with hydrogen peroxide or the redox cycling quinone me-
nadion, acetylation of K338/K341 lysine residues in OGG1 by EP300
was required for activity of OGG1 [32]. Importantly, our recent ﬁndings
indicate that PARP1 recruits EP300 to some gene promoters. Thus, it
sounds plausible to hypothesize that in our model PARP1 may recruit
EP300 to the site of oxidative DNA damage where it activates OGG1 to
stimulate DNA repair [33]. However, this hypothesis requires experi-
mental conﬁrmation.
OGG1 functions as a DNA glycosylase and excises 8-oxoguanine
from DNA, leaving behind an apurinic/apyrimidinic (AP) site. Thus, the
observation that OGG1 inhibition in PARP1 overexpressing and G1-
arrested cells led to accumulation of DNA strand breaks was somewhat
unexpected. These data suggest that OGG1 either contributes to the
removal of single strand lesions or another less speciﬁc DNA glycosylase
or lyase takes over the function of OGG1. The ﬁrst option is supported
by the in vitro ﬁndings showing that 3′-end 8-oxoguanine, which can
arise as a consequence of ionizing radiation and as a result of mis-
incorporation of 8-oxo-dGMP, required APE1 for the proper ligation of
DNA ends [34]. As OGG1 is involved in the 8-oxo-Gua removal in vivo,
the inhibition of OGG1 may maintain strand breaks carrying 8-oxo-Gua
at the lesions’ end(s).
Quite surprisingly, the deﬁciency of only OGG1 activity in PARP1
overexpressing and G1-arrested cells caused the loss of cell viability
after treatment with DNA damaging agents. A similar observation was
made in KG-1 human leukemia cells with an OGG1 mutation. In these
cells, loss of OGG1 activity resulted in the accumulation of 8-hydro-
xyguanine in DNA and enhanced sensitivity to irradiation [35]. On the
other hand, OGG1 overexpression protected human embryonic kidney
cells from platinum toxicity [36]. Furthermore, Ogg1−/− mice dis-
played lower repair capacity for 8-oxo-Gua and increased mutagenesis
frequencies due to GC to TA transversions [37]. Since base excision
repair of 7,8-dihydro-8-oxo-2′-deoxyguanosine is indispensable for cell
survival in certain conditions, inhibition of OGG1 may become a novel
anticancer treatment modality either in monotherapy or in combination
with DNA damaging agents.
In summary, inhibitors of CDK4/6 sensitize lung cancer cells to
oxidative stress-inducing anticancer drugs by creating a functional link
between RB1, PARP1, and OGG1. By repressing PARP1, CDK4/6 in-
hibitors indirectly impair OGG1-dependent base excision repair.
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